Islet transplants show promise in stopping dangerous blood sugar crashes
NCT ID NCT01897688
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether transplanting insulin-producing islet cells, along with immune-suppressing drugs, could safely prevent severe low blood sugar episodes in people with type 1 diabetes who don't feel warning signs. Ten participants received the transplant and were monitored for safety and effectiveness. The goal was to see if this approach could eliminate life-threatening hypoglycemic events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Islet cell transplant with Campath (immunosuppressive drug)
What this could lead to
If successful, this could offer a way to prevent dangerous low blood sugar episodes in people with type 1 diabetes, reducing the need for constant monitoring.
What could go wrong
This is a small, single-center study with only 10 participants, so results may not apply widely. The need for lifelong immunosuppression carries risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States